Your prediction
Pluristem Therapeutics Inc. Stock
Our community identified positive and negative aspects for Pluristem Therapeutics Inc. stock for the coming years. 1 users see the criterium "Revenue growth" as a plus for the Pluristem Therapeutics Inc. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Pluristem Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
M***** P*******
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pluristem Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pluristem Therapeutics Inc. | - | - | - | - | - | - | - |
| Enlivex Therapeutics Ltd. | 1.690% | -6.250% | 284.615% | 50.000% | 195.082% | -31.298% | -73.529% |
| Oramed Pharmaceuticals | -0.780% | 11.047% | -5.211% | 113.229% | 57.526% | 23.345% | -70.249% |
| Heron Therapeutics Inc. | -1.120% | 1.641% | 16.685% | -72.205% | -61.077% | -71.285% | -95.688% |